Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b
Stopped Discontinuation of product manufacturing by the funder prior to the start of participant enrollment
Conditions
- Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas
- Overexpression FGFR2b
Interventions
- DRUG: Bemarituzumab + Flot regimen
Sponsor
Institut Cancerologie de l'Ouest
Collaborators